[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sigmund Freud PrivatUniversitat\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":241},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,73,98,117,146,171,197,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100577854","metabolome-and-gut-microbiome-changes-during-smoking-cessation-in-long-term-drug-therapy-in-a-therapeutic-community-100577854",false,"NCT06803706","Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community","Metabolomic and Gut Microbial Biomarkers of Smoking Cessation Treatment in Long-term Drug Therapy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10\n* minimum age of 18 years\n* sufficient knowledge of the German language\n* willingness to quit smoking\n* willingness and ability to consent\n\nInclusion criteria for healthy controls :\n\n* minimum age of 18 years\n* sufficient knowledge of the German language\n* willingness and ability to consent\n\nExclusion Criteria:\n\n* lack of consent, inability to provide informed consent\n* age below 18,\n* acute psychotic symptoms or acute suicidal tendencies\n* cardiovascular disease\n* pregnancy or breastfeeding\n* severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score \\\u003C20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)\n* probiotic intake within the last 6 months,\n* ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study\n* prior participation in a smoking cessation programme",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.\n\nObjectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.\n\nMethods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.\n\nA cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.",[27,28,29,30],"Substance Use Disorder (SUD)","Alcohol Use Disorder (AUD)","Nicotine Addiction","Healthy Adult Participants",[32,33,34,35,36],"Metabolomics","Gut microbiome","Substance use disorder","nicotine addiction","smoking cessation","RECRUITING","2026-05-15",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":43,"type":41},"2025-05-05",{"date":45,"type":21},"2026-10-28",{"name":47,"class":48},"Sigmund Freud PrivatUniversitat","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100630069","tinder-fungus-as-an-adjunct-to-non-surgical-periodontal-therapy-for-periodontitis-100630069","NCT07482878","Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis","Tinder Fungus (Fomes Fomentarius) as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients diagnosed with Stage III or IV periodontitis\n* Patients who have not yet initiated periodontal therapy\n* Patients who have at least 20 remaining teeth\n* Patients who are willing to use an electric toothbrush\n* Patients who are willing to use interdental brushes\n\nExclusion Criteria:\n\n* Patients who have previously received treatment for periodontitis\n* Patients who have already undergone or initiated periodontal therapy\n* Patients with a known allergy or intolerance to any component of the toothpaste or the powder\n* Patients who are already using a product that contains tinder fungus (Fomes fomentarius)\n* Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.",{"count":58,"type":21},70,[24],"The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.\n\nThe main questions it aims to answer is:\n\n• Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.\n\nParticipants will:\n\n* Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days\n* Visit the clinic at least twice including a visit before and after the intervention\n* Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.",[62],"Periodontitis","NOT_YET_RECRUITING","2026-03-16",{"date":66,"type":41},"2026-03-19",{"date":68,"type":21},"2026-02",{"date":70,"type":21},"2028-12",{"name":47,"class":48},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100619584","endoscopic-screening-of-asymptomatic-patients-for-helicobacter-pylori-intestinal-metaplasia-and-barretts-mucosa-during-screening-colonoscopy-100619584","NCT07346521","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy - a Cross-sectional Study","G-SCOGE","Inclusion Criteria:\n\n* Age ≥ 30 years\n* Scheduled screening colonoscopy (either initial screening or surveillance following previously detected polyps)\n* Asymptomatic (no gastrointestinal symptoms)\n* Willingness and consent to undergo simultaneous gastroscopy with biopsy sampling\n* Written informed consent to participate in the study, including the use of histological findings and patient data for study analysis\n\nExclusion Criteria:\n\n* Known Helicobacter pylori infection or previous treatment for H. pylori\n* Current or recent proton pump inhibitor (PPI) therapy (\\\u003C 4 weeks)\n* Pre-existing gastrointestinal diseases (e.g., chronic gastritis, ulcer, gastric carcinoma)\n* Immunosuppression or relevant underlying diseases\n* Refusal to undergo additional gastroscopy or biopsy","30 Years",{"count":83,"type":21},1000,"OBSERVATIONAL","The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.\n\nEndoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer.\n\nThis study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa.\n\nThe main questions this study aims to answer are:\n\n* How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD?\n* Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and\u002For stomach cancer?\n\nAbout 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms).\n\nSmall tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes.\n\nDuring the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy.\n\nAll data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.",[87,88,89],"HELICOBACTER PYLORI INFECTIONS","Intestinal Metaplasia","Barett's Esophagus","2026-03-05",{"date":92,"type":41},"2026-03-09",{"date":94,"type":41},"2025-12-16",{"date":96,"type":21},"2026-12-16",{"name":47,"class":48},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100616005","quantitative-net-water-uptake-as-a-predictor-of-functional-outcomes-after-intravenous-thrombolysis-in-acute-ischemic-stroke-international-multicenter-observational-retrospective-study-100616005","NCT07299981","Quantitative Net Water Uptake as a Predictor of Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Stroke International Multicenter Observational Retrospective Study","Inclusion Criteria:\n\n* Acute ischemic stroke treated with intravenous thrombolysis\n* Imaging with non-contrast cranial CT on admission\n* Follow-up imaging with non-contrast cranial CT or MRI 12-24 hours after IVT\n* Final Infarct volume \\> 5ml\n* ASPECTS available\n\nExclusion Criteria:\n\n* Known use of oral anticoagulation (OAC) on admission\n* Preexisting ischemic infarction on admission non-contrast cranial CT\n* Patients with large vessel occlusion AIS who underwent mechanical thrombectomy\n* Low imaging quality precluding radiological measurements\n* Severe white matter lesions precluding radiological measurements\n* No ASPECTS",{"count":105,"type":21},200,"While the effectiveness of intravenous thrombolysis (IVT) decreases over time, patients show considerable variability in how quickly their ischemic core progresses. Quantitative net water uptake (NWU) has emerged as a biomarker indicating blood-brain barrier disruption and may better reflect the \"tissue clock\" than time alone. Low NWU is associated with favorable outcomes, whereas high NWU predicts poor outcomes and futile recanalization. The study aims to determine whether NWU measured on initial non-contrast CT is a treatment effect modifier for the IVT therapy.",[108],"Ischemic Stroke","2026-01-15",{"date":111,"type":41},"2026-01-20",{"date":113,"type":21},"2026-01-01",{"date":115,"type":21},"2027-07-01",{"name":47,"class":48},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":126,"conditions":127,"keywords":133,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006","NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.",{"count":125,"type":21},462,"Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[128,129,130,131,132],"Stroke","Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","Acute Ischemic Stroke",[134,135,129,136,137],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","2025-12-10",{"date":140,"type":41},"2025-12-23",{"date":113,"type":21},{"date":143,"type":21},"2026-04-30",{"name":47,"class":48},7,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":156,"studyType":84,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100610716","detection-of-microplastics-in-patients-with-periodontitis-100610716","NCT07231198","Detection of Microplastics in Patients With Periodontitis","Detection of Microplastics in Patients With Periodontitis - a Cross-sectional Study","micropl_perio","Inclusion Criteria:\n\n* Adults aged 18 and over\n* Gender: Female \u002F male \u002F diverse\n* Patients\n\n  * who have been diagnosed with stage III and IV periodontitis.\n  * who have not yet started periodontal treatment.\n  * who still have at least 20 teeth. Providing written consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients\n\n  * who have already been treated for periodontitis\n  * who have already undergone\u002Fbegun periodontitis treatment",{"count":155,"type":21},25,"1 Day","Plastic particles known as microplastics are now a ubiquitous part of the environment. Human exposure to microplastics occurs through the consumption of contaminated food and polluted air, which affect the intestinal system. Several studies have detected the presence of microplastics in various parts of the human digestive system, e.g., in feces. Unfortunately, little is known about the presence of microplastics in the mouth as the primary part of the digestive system. Periodontal pockets can be considered an ideal deposition site for microplastics. Since microplastics are suspected of being an immunomodulatory factor, there is great interest in their presence in subgingival plaque and their possible exacerbation of chronic inflammatory diseases such as periodontitis. The following study aims to clarify the presence, classification, and concentration of microplastics in subgingival plaque. No comparable study has been identified to date.",[159,62],"Periodontal Diseases",[161,162],"periodontitis","microplastics","2025-11-16",{"date":165,"type":41},"2025-11-19",{"date":167,"type":21},"2026-02-01",{"date":169,"type":21},"2028-02-01",{"name":47,"class":48},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":72},"100569025","the-study-is-about-the-inuence-of-the-combination-of-music-and-noise-cancelling-as-a-non-pharmacological-aid-in-reducing-anxiety-and-discomfort-during-wisdom-tooth-removal-the-level-of-fear-is-measured-by-a-questionnaire-which-the-patients-answer-twice-and-a-measurement-of-the-heartbeat-100569025","NCT06688877","The Study is About the influence of the Combination of Music and Noise Cancelling as a Non-pharmacological Aid in Reducing Anxiety and Discomfort During Wisdom Tooth Removal. The Level of Fear is Measured by a Questionnaire Which the Patients Answer Twice and a Measurement of the Heartbeat","Einfluss Der Kombination Von Musik Und Noise Cancelling Als nichtmedikamentöse Unterstützung Bei Angst Und Unwohlsein während Der Weisheitszahnentfernung","Inclusion Criteria:\n\n* willing to participate in the clinical trial, understood and signed the information sheet\n\nExclusion Criteria:\n\n* younger than 18 years old\n* hearing impairment",{"count":179,"type":21},156,"The goal of this clinical trial is to learn if the reduction of the noises (through head phones with music and noise cancelling) that occur during wisdom teeth removal, leads to a significant reduction in fear levels in patients compared to patients who do not have any noise reduction. The main questions it aims to answer are:\n\nDo music and noise cancelling help patients to have less fear during wisdom teeth removal surgery by reducing the sounds of the surgery? Is there a difference between just the noise cancelling function or is it better to combine noise cancelling and music together?\n\nParticipants will:\n\nJust come to their regular appointment (wisdom teeth removal) to our clinic, no follow ups needed. All participants will answer one questionnaire before and one after the surgery. All of them will have their rate of heartbeat measured for three times (before, during and after surgery, measured by a puls oximeter on the finger). They will be allocated to one of the three study groups (no headphones, headphones with noise cancelling or headphones with noise cancelling and music).",[182,183,184],"Fear Anxiety","Wisdom Tooth Removal","Heart Rate",[186,187,188],"fear level","wisdom teeth removal","noise reduction by music and noise cancelling","2024-11-13",{"date":191,"type":41},"2024-11-14",{"date":193,"type":21},"2024-11-18",{"date":195,"type":21},"2025-06-29",{"name":47,"class":48},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100557529","socket-preservation---a-randomized-clinical-implementation-in-a-student-setting-100557529","NCT06539299","Socket Preservation - A Randomized Clinical Implementation in a Student Setting","Socket Preservation - How Successful is the Method for Inexperienced Practitioners? A Randomized Clinical Implementation in a Student Setting","Inclusion Criteria:\n\n* Study participants have signed patient information and consent form\n* Age between 18-65 years, all genders included\n* Study participants who are considering a planned extraction of a mandibular posterior tooth with subsequent treatment with an implant\n* Study participants with medical and anatomical conditions that correspond to the applicable instructions for use\n* Study participants agree to student treatment\n\nExclusion Criteria:\n\n* Study participants under 18 years of age\n* Study participants with allergies or undesirable reactions to the materials used - Patients with uncontrolled diabetes mellitus (HbA1C value \\>8%)\n* Heavy smokers (\\>10 cigs\u002Fday)\n* Previous general medical conditions that influence bone metabolism (Bone metabolic diseases such as osteopetrosis, osteomalacia, Paget's disease, metabolic diseases such as hyperthyroidism, renal osteopathy, oophorectomy, uncontrolled diabetes mellitus type 2), malignant neoplasms, chemotherapy\u002Fradiation therapy in the head and neck area and immunocompromised patients)\n* which can be determined clinically or radiologically pathological symptoms in the oral cavity or on the alveolar processes or the adjacent regions, untreated acute or chronic disease of the periodontium, untreated disease of the oral mucosa - drug abuse, alcohol disease or abuse","65 Years",{"count":206,"type":21},51,[24],"Preserving the ridge dimension after tooth extraction aims to avoid the need for bone augmentation procedures before implant placement. This study aims to show that socket preservation procedure is a safe, easy and predictable method that stabilizes the bone situation when late implantation is planned.",[210,211,212],"Alveolar Bone Loss","Dental Implant","Bone Augmentation","2024-08-01",{"date":215,"type":41},"2024-08-06",{"date":217,"type":21},"2024-09-01",{"date":219,"type":21},"2027-03-01",{"name":47,"class":48},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100557528","dentin-hypersensitivity---varnish-or-laser-100557528","NCT06539286","Dentin Hypersensitivity - Varnish or Laser?","Dentin Hypersensitivity - Varnish or Laser? A Randomized Clinical Study Comparing Three Wavelengths (2940 nm, 1064 nm and 970 nm) and the Desensitizer Gluma","Inclusion Criteria:\n\n* all genders\n* 18-70 years\n* good general health\n* at least two hypersensitive teeth in either jaw\n* initial VAS-score \\>3\n\nExclusion Criteria:\n\n* Active carious lesions, insufficient restorations, enamel cracks, reversible pulpitis\n* Active periodontal disease, periodontal surgery (in the last 6 months)\n* Bleaching procedure in the last 3 months\n* Analgetic use in the last 72 hours\n* Pregnant\u002Flactating women","70 Years",{"count":230,"type":21},80,[24],"Dentin hypersensitivity is a common condition described as a short and sharp pain caused by thermal, evaporative, tactile, osmotic, or chemical stimuli to exposed dentin that cannot be related to another defect or dental pathology. The variety of treatment options and products on the market might seem overwhelming. This study aims to show that laser treatments are efficient in reducing pain scores compared to a desensitizing agent (Gluma). 80 patients with at least two hypersensitive teeth will be enrolled in this study. Patients will be divided randomly into four groups (control group (Gluma), laser group 1 (2.94 µm wavelength), laser group 2 (1064 nm wavelength), laser group 3 (970 nm wavelength)). Visual Analog Scale will be measured before treatment, right after treatment, one week after treatment, one month after treatment, three months after treatment. Mixed Anova's and descriptive analysis will be used for statistical evaluation.",[234],"Dentin Hypersensitivity",{"date":215,"type":41},{"date":237,"type":21},"2024-09-02",{"date":239,"type":21},"2024-12-14",{"name":47,"class":48},""]